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A B s T r A C T
Background: immunoglobulin A nephropathy (igAN) 
is characterised by high variability in clinical course and 
outcome. Accurate prediction of prognosis is needed 
to optimise treatment. Urinary α1-microglobulin and 
β2-microglobulin are markers of tubulointerstitial 
injury and predict the risk of end-stage renal disease 
(Esrd) in idiopathic membranous nephropathy. We 
questioned the relevance of these markers in igAN. 
Methods: We included patients with biopsy proven 
igAN, who were evaluated for proteinuria in our centre 
between 1995 and 2007. data were analysed using 
univariate and multivariate Cox regression for the 
outcome variables Esrd and progression (rise in serum 
creatinine of >50% or start of immunosuppressive therapy). 
results: seventy patients (71% men) were selected. 
Median age was 39 years, median serum creatinine 140 
μmol/l, and median proteinuria 2.4 g/day. Median urinary 
α1-microglobulin excretion was 23.5 μg/min (range 3.5-275.3) 
and median urinary β2-microglobulin excretion was 0.4 
μg/min (range 0.1-62.1). Both α1m and β2m correlated 
significantly with serum creatinine (r = 0.65, p<0.01 and 
r = 0.62, p<0.01) and total proteinuria (r = 0.35, p<0.01 and 
r = 0.28, p<0.05). during follow-up (median 75 months) 
25 patients (36%) developed Esrd, and 46 patients (66%) 
showed progression. 19 patients (27%) were treated with 
immunosuppressive agents. in univariate analysis urinary 
α1- and β2-microglobulin predicted Esrd and progression. 
in multivariate analysis only serum creatinine and urinary 
protein were independent predictors of both outcomes. 
Conclusion: Urinary excretion of low molecular weight 
proteins did not offer an advantage over total proteinuria 
and serum creatinine in predicting prognosis in patients 
with igAN.
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i N T r o d U C T i o N
Immunoglobulin A nephropathy (IgAN) is the most 
common glomerulonephritis worldwide. The natural 
history is quite variable and published data must be 
interpreted with caution since many patients with mild 
disease may never come to clinical attention or undergo 
a renal biopsy. End-stage renal disease (ESRD) develops 
in 20 to 30% of patients with IgAN within 20 years after 
diagnosis.1-4 
Although there is a lack of randomised controlled trials, 
data suggest that a minority of patients may benefit from 
immunosuppressive treatment.5-8 Ideally, such treatment 
should be restricted to patients who will progress to ESRD. 
Several variables have been identified as predictors of 
prognosis i.e. elevated serum creatinine concentration,3,9-13 
severe proteinuria,9,14-17 arterial hypertension9,15,16 and 
histological characteristics.3,10,14,15 Few studies have showed 
that clinical features evaluated after one year of follow-up 
predicted prognosis more accurately than at the time 
of presentation.17,18 Recently Reich et al. reported that 
persistent proteinuria is the strongest predictor of poor 
renal outcome in IgAN and that sustained reduction of 
proteinuria to <1 g/24 hour is associated with a good 
prognosis.19 Unfortunately, most markers are not very 
accurate, with low sensitivity and specificity.
In idiopathic membranous nephropathy, high-risk 
patients can be identified in an early stage by measuring 
low-molecular-weight proteins such as α1-microglobulin 
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(α1m) and β2-microglobulin (β2m) with a sensitivity of 
83% and a specificity of 97%.20-22 We aimed to determine 
whether the excretion of low-molecular-weight (LMW) 
proteins adds to predicting prognosis in patients with 
IgAN. 
s U B J E C T s  A N d  M E T H o d s
Population
Since 1995, we have performed standardised protein 
measurements in patients with proteinuria due to 
glomerular diseases.20,21 Patients are referred to our 
medical centre from hospitals located mainly in the 
south-eastern part of the Netherlands. For the present 
study we analysed the data of adult patients with biopsy 
proven IgA nephropathy who were evaluated for proteinuria 
in our centre between 1995 and 2007, and followed 
thereafter. Patients with other causes of IgA-positive 
glomerular staining (systemic lupus erythematosus, 
Henoch-Schönlein purpura or liver disease) or a follow-up 
of less than 12 months, were excluded from analysis. 
Baseline measurement
Gender, ethnicity, age, body weight and height were 
recorded at the time of measurement. Details of the 
measurements have been described.21 Two 24-hour 
urine samples were obtained for measurement of 
creatinine and total protein. The excretion of the low- 
and high-molecular-weight proteins was measured under 
standardised conditions. A urinary pH >6.0 is necessary 
to allow reliable measurements of urinary β2m. Therefore, 
patients took 4000 mg of oral sodium bicarbonate the 
evening before the measurement. On arrival at the 
ward, the patients took an additional 2000 to 4000 
mg sodium bicarbonate and up to 500 ml of tap water 
was given to enforce diuresis. The patients remained 
supine for two hours except for voiding. Blood pressure 
measurements were taken using an automated device 
(DINAMAP, Criticon, Tampa FL) with six consecutive 
readings registered every five minutes after ten minutes 
rest; these readings were used to calculate the mean 
arterial pressure (MAP). Measurement of urinary 
pH, β2m, α1m, immunoglobulin G (IgG), transferrin, 
albumin, total protein and creatinine was performed. 
Beta-2-microglobulin excretion was only measured in 
urine with a pH >6.0. Laboratory parameters were 
measured in blood samples collected in the middle of the 
urine collection period.
The use of angiotensin-converting enzyme inhibitors 
(ACEIs) and/or angiotensin II type 1 receptor antagonists 
(ARBs), calcium channel blockers, other antihypertensive 
agents, diuretics, and non-steroidal anti-inflammatory 
drugs (NSAIDs), as well as HMG-CoA-reductase 
inhibitors, was recorded. Current or previous use of 
corticosteroids, other immunosuppressive agents or fish 
oil was registered.
Serum creatinine, cholesterol, urinary total protein and 
creatinine were measured with standard automated 
techniques. Urinary proteins were measured as described 
before.23 
follow-up
After baseline measurements, patients were commended 
to the care of their local physicians. Immunosuppressive 
therapy was advised to patients with progressive renal 
disease. We collected data on serum creatinine, albumin, 
cholesterol and urea, total urinary protein and creatinine 
levels, blood pressure, body weight and exposure to 
medication during follow-up from medical records. 
Calculations and definitions 
Body mass index (BMI) was calculated from body weight 
and height at baseline. MAP during follow-up was 
calculated as the diastolic pressure plus one third of 
the pulse pressure. The glomerular filtration rate at 
baseline and follow-up was estimated (eGFR) using 
the abbreviated Modification of Diet in Renal Disease 
(MDRD) equation.24,25 Start of follow-up was defined as 
the time of standardised measurement of proteinuria, 
regardless of the first assessment suggestive of renal 
disease. We defined the following two renal outcomes: 
ESRD and progression of renal disease. ESRD was 
defined as initiation of dialysis, renal transplantation or 
an eGFR <15 ml/min per 1.73 m2. Progression of renal 
disease was defined as an elevation in serum creatinine 
of 50% or more since the baseline measurement, the 
start of immunosuppressive therapy or the development 
of ESRD. 
statistical analysis
Missing values for urinary protein concentration in the 
24-hour urine samples were imputated by using the 
urinary protein-creatinine ratio which was obtained from 
the two-hour sample, and by using serum albumin. 
Missing values for low-molecular-weight proteins were 
not imputated. 
All baseline variables were compared for patient groups 
by χ2-test if dichotomous, one-way ANOVA if continuous 
and after log transformation if skewed. Each continuous 
baseline variable was divided into tertiles and plotted in a 
Kaplan-Meier curve for visual inspection.
Possible collinearity for univariate significant predictors 
was checked. Predictors that had a Spearman’s rho smaller 
than 0.800 were entered into a multivariate Cox model. 
A backward stepwise selection algorithm, criteria for 
exclusion being a likelihood ratio test with p-value greater 
than 0.05 and smaller than 0.10 for inclusion, was used. 
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Table 1. Clinical and demographic characteristics at baseline
Total group Progression No progression  
rise in serum 
creatinine >50%
Therapy p
n (% male) 70 (71.4%) 35 (74.3%) 11 (81.8%) 24 (62.5%) 0.436
Age (years) 39 (17-70) 36.0 (17-70) 37 (25-59) 45.5 (20-66) 0.164
BMI (kg/m2) 26.2 (19.4-41.0) 26.1 (20.4-31.1) 27.5 (21.2-33.2) 26.3 (19.4-41.0) 0.605
MAP (mmHg) 101.3 (73-133.7) 104 (83-133.7) 99.8 (73-112) 94.3 (80.0-133.2) 0.113
Urinary protein (g/d) 2.4 (0.4-24.4) 2.9 (0.5-12.6) 3.6 (0.4-24.3) 1.7 (0.4-9.6) 0.090
Protein-creatinine ratio (g/10 mmol) 2.9 (0.5-18.2) 3.5 (1.0-16.1) 4.5 (0.6-18.2) 1.2 (0.5-13.3) 0.093
Serum creatinine (μmol/l) 139.5 (70-366) 149 (76-366) 186 (100-274) 112 (70-172) <0.001
Serum urea (μmol/l) 8.3 (4-36) 9.1 (4-36) 11.1 (6-22) 6.3 (4-14) 0.007
Serum albumin (g/l) 38.0 (21-46) 38.0 (21-46) 37.0 (29-45) 39.0 (30-44) 0.847
Serum cholesterol (mmol/l) 5.7 (3.5-8.9) 5.9 (3.6-8.7) 5.1 (3.6-8.9) 5.7 (3.5-7.2) 0.468
MDRD4 (ml/min/1.73 m2) 48.2 (16.5-95.5) 44.9 (16.5-86.7) 37.1 (22.3-82.0) 54.7 (36.3-95.5) 0.003
α1-microglobulin excretion (μg/min) 23.5 (3.5-275.3) 30.6 (3.5-275.3) 48.0 (7.8-192.0) 14.9 (4.1-48.4) 0.010
β2-microglobulin excretion (μg/min) 0.4 (0.1-62.1) 1.1 (0.1-62.1) 1.15 (0.1-36.0) 0.30 (0.1-27.0) 0.077
IgG excretion (mg/d) 111.4 (11.3-1327.2) 144.8 (16.2-1327.2) 111.4 (11.3-900.1) 68.2 (13.5-786.9) 0.038
ESRD 35.70% 65.70% 18.20% 0% <0.001
Time until ESRD of last follow-up (months) 74.6 (2.2-145.6) 72.7 (2.2-145.6) 97.5 (6.1-135.5) 76.9 (12.9-125.9) 0.676
Time until progression or last follow-up (months) 39.4 (0.2-125.9) 28.1 (0.5-114.5) 2.1 (0.2-75.6) 76.9 (12.9-125.9) <0.001
Interval between biopsy and referral* (months) 2.0 (0-209.7-) 5.0 (0-187.5) 0.7 (0-98.9) 1.8 (0-209.7) 0.965
Interval between onset and referral (months) 29.3 (219.7-2.0) 38.6 (195.9-4.1) 36.0 (179.7-2.3) 8.8 (219.7-2.0) 0.592
Use of ACEIs/ARBs before baseline 80.00% 80.00% 81.80% 79.20% 0.984
Use of diuretics before baseline 30.00% 34.30% 27.30% 25.00% 0.729
Use of other antihypertensive medication 34.30% 37.10% 45.50% 25.00% 0.437
Use of immunosuppressive treatment before 
baseline
4.30% 5.70% 9.10% 0.00% 0.393
Use of ACEIs/ARBs during follow-up 100.00% 100.00% 100.00% 100.00%
Use of diuretics during follow-up 68.60% 71.40% 90.90% 54.20% 0.082
Use of other antihypertensives during follow-up 54.30% 62.90% 63.60% 37.50% 0.126
Use of immunosuppressive drugs during follow-up 27.14% 22.86% 100.00% 0.00% <0.001
data expressed as median (range). *in a few patients biopsy was performed after evaluation for proteinuria. 
BMi = body mass index; MAP = mean arterial blood pressure; Mdrd4 = modification of diet in renal disease equation; Esrd = end-stage renal 
disease; ACEi= angiotensin-converting enzyme inhibitors; ArB=angiotensin ii type 1 receptor antagonist.
P values are from χ2-test or ANoVA comparing the three groups: rise in serum creatinine, therapy and non-progressors.
Possible interactions, based on plausible mechanism, were 
entered and tested too. The most parsimonious model with 
the best fit, using generalised R2, was considered most 
appropriate.26 Internal validation of the selected model was 
done with a bootstrapping procedure using 1000 samples. 
The predictive value of this model was investigated by the 
area under the receiver operating characteristics (ROC) 
curve. 
r E s U l T s
Baseline characteristics and outcome variables
Initial demographic, clinical and laboratory data of 70 
patients are listed in table 1. In the majority of patients 
(57%) proteinuria was >2.0 g/day and the estimated GFR 
<60 ml/min/1.73 m2. Eighty percent of the population 
were taking ACEIs or ARBs at the time of evaluation for 
proteinuria. Median duration of follow-up was 74 months. 
The time period between onset of renal disease or biopsy 
and subsequent referral to our centre varied. In 60% of 
patients the time between biopsy and referral was less than 
six months.
During follow-up all patients were treated with ACEIs and/
or ARBs. Immunosuppressive therapy was initiated in 19 
patients, the majority of them (74%) were treated with 
cyclophosphamide combined with prednisone. Twenty-five 
patients (36%) developed ESRD, with the shortest survival 
time being two months. Five- and eight-year renal survival 
rates from baseline were 78 and 66% (figure 1). In 46 
(66%) patients progression of renal disease occurred 
based on an increase in serum creatinine of >50% (n=35), 
or initiation of immunosuppressive therapy (n=11). Thus, 
of 19 patients who received immunosuppressive therapy 
during follow-up, eight patients were treated because 
of a rise in serum creatinine of more than 50%. In 11 
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patients treatment was started earlier. These patients 
were characterised by higher serum creatinine values at 
baseline and more severe proteinuria (table 1). 
low-molecular-weight proteins
Alpha-1-microglobulin levels were not available for two 
patients, while β2m levels could not be measured in nine 
patients due to a urinary pH <6.0. The urinary excretion 
of both α1m and β2m was increased in patients with IgAN, 
with median levels of 23.5 μg/min (reference value <10 μg/
min) and 0.4 μg/min (reference value <0.2 μg/min). 
There was a high correlation between α1m and β2m (r = 0.86, 
p<0.01). Both α1m and β2m correlated significantly with 
serum creatinine (r = 0.65, p <0.01 and r = 0.62, p<0.01), 
IgG excretion (r = 0.59, p<0.01 and r = 0.58, p<0.01), and 
total proteinuria (r = 0.35, p<0.01 and r = 0.28, p<0.05). 
Predictors of outcome 
End-stage renal disease
Urinary α1-microglobulin, β2-microglobulin and IgG 
excretion, serum creatinine and urea levels, total urinary 
protein, eGFR and the use of diuretics before baseline 
were all significantly associated with ESRD. When 
evaluating tertiles of α1m, renal survival in the highest 
tertile was markedly lower compared with that in the 
lowest and middle tertiles (94 vs 63% at five years, 85 vs 
44% after eight years, p=0.001) (figure 2). Only one patient 
within the lowest tertile of urinary β2m developed ESRD. 
Therefore, renal survival in the lowest tertile of β2m was 
higher than in the middle and highest tertile (figure 3). 
After multivariate Cox regression analysis only baseline 
serum creatinine and total proteinuria proved significant 
predictors of ESRD when correcting for therapy (table 2). 
Thus, neither α1-microglobulin nor β2-microglobulin 
figure 2. Renal survival curve for tertiles of 
α1-microglobulin in patients with IgAN
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figure 3. Renal survival curve for tertiles of 
β2-microglobulin in patients with IgAN
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figure 1. Renal survival curve in patients with IgAN
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were independent predictors of ESRD. Of note, patients 
who were treated with immunosuppressive agents during 
follow-up were less likely to develop ESRD. 
Progression of renal disease
Urinary α1-microglobulin, β2-microglobulin and IgG 
excretion, serum creatinine and urea levels, total urinary 
protein, eGFR and age, were significant predictors of 
progression in univariate analysis. Multivariate Cox 
regression showed that only serum creatinine and total 
urinary protein were independent significant predictors of 
progression (table 2).
d i s C U s s i o N
Our data clearly indicate that the urinary excretion of 
low-molecular-weight proteins does not predict prognosis 
in IgAN more accurately than total proteinuria. To our 
knowledge we are the first to report on the prognostic 
value of urinary excretion of α1-microglobulin and 
β2-microglobulin in IgAN. Others have found a highly 
significant relation between tubulointerstitial damage and 
the presence of unspecified, urinary LMW proteins, in a 
small cohort of patients with IgAN.27 Woo et al. reported 
a higher incidence of chronic renal failure in 60 patients 
with IgAN who presented with LMW proteinuria and 
were followed for six years.28 However, patients with LMW 
proteinuria had more severe proteinuria and higher serum 
creatinine levels.
In our patients with IgAN urinary excretion of α1m and β2m 
exceeded normal values. Renal survival was significantly 
lower in patients with values of urinary α1m and β2m in 
higher tertiles. We observed a difference when comparing 
renal survival curves for tertiles of urinary α1m and β2m 
excretion. This apparent discrepancy can be explained by the 
fact that β2m could not be measured in nine patients due to a 
low urinary pH. These patients were characterised by higher 
serum creatinine levels and more severe proteinuria. Thus, 
missing values are not at random but reflect an impairment of 
renal function and bicarbonate excretion. This illustrates the 
limitations of β2m as a prognostic marker. Both urinary α1m 
and β2m predicted ESRD and progression of renal disease in 
univariate analysis. However, in multivariate analysis they 
did not prove to be independent predictors of either outcome. 
These findings are in contrast with previous reports on the 
good performance of LMW proteins as prognostic markers in 
patients with idiopathic membranous nephropathy. Urinary 
α1m and β2m are considered to reflect tubulo-interstitial 
injury. In general, the presence and extent of tubulo-interstitial 
injury determines renal outcome. From this perspective, the 
difference in the predictive value of LMW proteins between 
IgAN and idiopathic membranous nephropathy is remarkable. 
Of note, the predictive value of LMW proteins (such as α1m) in 
idiopathic membranous nephropathy was validated in patients 
with no or moderate renal impairment, defined as a serum 
Table 2. Hazard ratios (HR) and confidence intervals (CI) of significant baseline predictors of ESRD or progression 
of renal disease after univariate and multivariate analysis
Variable Univariate analysis Multivariate analysis
Hr (95% Ci) Hr (95% Ci)
ESRD α1-microglobulin (μg/min) 1.015 (1.008 – 1.023)
β2-microglobulin (μg/min) 1.06 (1.022 – 1.099)
IgG excretion (mg/d) 1.002 (1.001 – 1.004)
Use of diuretics before referral 2.922 (1.197 – 7.132)
MDRD4 ml/min/1.73 m
2 0.929 (0.897 – 0.962)
Protein-creatinine ratio (g/10 mmol) 1.133 (1.022 – 1.255)
Serum urea (mmol/l) 1.161 (1.099 – 1.226)
Serum creatinine (μmol/l) 1.018 (1.012 – 1.025) 1.022 (1.013 – 1.038)
Total urinary protein (g/d) 1.160 (1.061 – 1.268) 1.241 (1.029 – 1.781)
Immunosuppressive therapy 0.843 (0.336 – 2.115) 0.179 (0.010 – 0.921)
Generalised R2 = 0.508
Progression α1-microglobulin (μg/min) 1.013 (1.008 – 1.018)
β2-microglobulin (μg/min) 1.033 (1.006 – 1.061)
IgG excretion (mg/d) 1.002 (1.001 – 1.003)
MDRD4 ml/min/1.73m
2 0.972 (0.955 – 0.990)
Protein-creatinine ratio (g/10 mmol) 1.119 (1.039 – 1.205)
Serum urea (mmol/l) 1.102 (1.055 – 1.151)
Serum creatinine (μmol/l) 1.009 (1.005 – 1.013) 1.009 (1.005 – 1.014)
Total urinary protein (g/d) 1.216 (1.116 – 1.325) 1.213 (1.112 – 1.362)
Generalised R2 = 0.368
Esrd = end-stage renal disease; Mdrd = modification of diet in renal disease equation, igG = immunoglobulin G.
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creatinine <135 μmol/l. However, even within the subgroup 
of patients with IgAN and a serum creatinine level of <135 
μmol/l, α1m does not allow identification of high-risk patients. 
This difference is illustrated in the panels of figure 4. From 
the figure it is evident that levels of α1m are higher in patients 
with idiopathic membranous nephropathy. These patients 
presented more frequently with nephrotic range proteinuria. 
Thus, the prognostic value of these LMW proteins may be 
confined to glomerulopathies characterised by nephrotic 
range proteinuria. 
We found baseline serum creatinine and proteinuria to 
predict ESRD and progression of renal disease. The relation 
between serum creatinine and ESRD is to be expected, 
since a patient with a higher serum creatinine concentration 
will develop ESRD at an earlier time-point, even if the rate 
of renal function deterioration is similar. To overcome 
this problem we defined a 50% or more increase of serum 
creatinine concentration as progression. We chose a 50% rise 
to be sure that no patients who had a minor increase were 
marked as progressors. Since multivariate analysis regarding 
the outcome ESRD implied that the natural progression of 
IgAN is influenced by immunosuppressive therapy, this was 
considered an end-point. The use of initiation of immunosup-
pressive therapy as an end-point can be debated. In our study, 
19 out of 70 patients received immunosuppressive therapy 
during follow-up. In eight patients, treatment was started 
after serum creatinine had increased by 50% or more. 
The remaining 11 patients received immunosuppressive 
treatment before reaching this 50% rise in serum creatinine. 
These patients were characterised by high serum creatinine 
and more severe proteinuria at baseline. Further delay of 
treatment was considered inappropriate by their physicians. 
As such, these patients reflect current treatment practice in 
our region. At the start of therapy, mean serum creatinine 
was 221 μmol/l, clearly pointing to the severity of IgAN. Even 
with progression as outcome, serum creatinine level and total 
urinary protein excretion remained significant, independent 
predictors. 
The observation that serum creatinine concentration is a 
significant, independent predictor of progression of renal 
disease implies that an accelerated rather than a linear decline 
in renal function occurs in the course of the disease. In 
order to correct for the possible confounding effect of using 
initiation of immunosuppressive therapy as an end-point, we 
reanalysed the data using an increase of serum creatinine 
of >50% as only end-point. Serum creatinine concentration 
remained a significant predictor, which possibly reflects that 
patients with an increased serum creatinine are more likely to 
progress or progress at a faster rate than those with no renal 
impairment. Our findings support observations reported 
by others and are in line with the hypothesis that loss of 
nephrons gives rise to hyperfiltration of a reduced number 
of nephrons leading to further destruction of nephrons and 
an accelerated deterioration of renal function.29,30 
Although data are scarce, immunosuppressive medication 
may be of benefit for patients failing a supportive approach 
figure 4B. Correlation between α1-microglobulin and 
proteinuria in patinets with IgAN
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figure 4A. Correlation between α1-microglobulin and 
proteinuria in patinets with iMN
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and at high risk for progressive loss of renal function. In order 
to avoid unnecessary immunosuppressive therapy, a model 
with a high specificity is required to guide clinical decisions 
regarding treatment. When constructing a receiver operating 
characteristics curve (ROC), our model predicting ESRD 
using serum creatinine concentration and urinary protein 
concentration has an area under the curve (AUC) of 0.88 
(95% CI 0.78 to 0.95). When predicting progression of renal 
disease using the same variables, the AUC was 0.80 (95% 
CI 0.69 to 0.91). Although these values indicate a reasonably 
good performance of our models, closer examination of data 
shows that a specificity of 90% is accompanied by a low 
sensitivity (50 to 60%). Our models are therefore unsuitable 
to guide clinical decisions. The identification of more 
accurate prognostic markers remains essential.
Admittedly, this study has several limitations. First, it 
describes a relatively small number of patients. Second, 
when compared with other reported populations, eGFR is 
lower and proteinuria is more severe in our cohort despite 
a comparable blood pressure. A large percentage of patients 
showed fast progression and many patients developed ESRD. 
This may be due to a selection bias since patients with 
stable serum creatinine and moderate proteinuria are less 
likely to be biopsied and/or referred to our medical centre. 
Since many patients were biopsied in another hospital and 
material was unavailable, we were unable to correlate urinary 
α1m and β2m with histopathological characteristics. On the 
other hand, in contrary to earlier populations examined, 
this cohort is comprised of patients who were all treated 
with ACEIs and/or ARBs, an important element of therapy 
nowadays. Furthermore, we ruled out an effect of therapy 
while analysing data. Finally, the lack of a validation group, as 
in every other study evaluating the prognostic predictors for 
progression of IgAN, was corrected for by bootstrapping. 
C o N C l U s i o N
Urinary excretion of the low-molecular-weight proteins 
α1-microglobulin and β2-microglobulin does not add 
to predicting prognosis of IgAN. Serum creatinine 
concentration and urinary protein excretion are the most 
potent predictors of progression of IgA nephropathy. 
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